Results 101 to 110 of about 5,801,283 (182)

Tissue levels of PIVKA-II and vitamin K in patients with hepatocellular carcinoma. Studies on the mechanism of the production of PIVKA-II.

Kanzo, 1988
Masataka OKUNO, Yasushi FUKUTOMI, Makoto SHIMAZAKI, Tetsuya YAMADA, Nobuo MURAKAMI, Kiyoshi KAWAI, Yasutoshi MUTO, Masahide OMORI   +7 more
openaire   +3 more sources

Prognostic Significance of Combined α-Fetoprotein and PIVKA-II for Hepatocellular Carcinoma After Hepatectomy. [PDF]

J Hepatocell Carcinoma
Wen J, Yang T, Huang M, Xiang B, Yang C, Zhang J.   +5 more
europepmc   +1 more source

Assay performance verification and reference interval establishment for PIVKA-II on the Roche cobas e 801. [PDF]

BMC Gastroenterol
Zhao Y, Liu Z, Xiao C.
europepmc   +1 more source

Assessment of the diagnostic performance and influencing factors of AFP and PIVKA-II in hepatocellular carcinoma. [PDF]

Discov Oncol
Wang Y, Liu M, Xie Z, Lin J, Du S, Zhang C, Wang Z, Gao Y.   +7 more
europepmc   +1 more source

Surveillance of hepatocellular carcinoma (HCC) patients using Protein Induced by Vitamin K (PIVKA-II): A cost-utility analysis for Hong Kong. [PDF]

PLoS One
Yuen MF, Wastlund D, Lin TTY, Zheng Q, Chen J, Ko KL.   +5 more
europepmc   +1 more source

PIVKA-II concentrations in patients with cystic fibrosis. [PDF]

Journal of Clinical Pathology, 1992
E A Cornelissen, A F van Lieburg, C G van Oostrom, L Monnens   +3 more
openaire   +1 more source

Characteristics of Recurrent Hepatocellular Carcinoma Based on Serum AFP, PIVKA-II, and Genetic Mutations. [PDF]

Medicina (Kaunas)
Cho IS, Ahn KS, Jeong S, Kim TS, Kim MJ, Yang SK, Cho S, Kim YH.   +7 more
europepmc   +1 more source

Diagnostic Performance of AFP, PIVKA-II, and the ASAP Score for Distinguishing Hepatocellular Carcinoma With and Without Portal Vein Tumor Thrombus: A Retrospective Single-Center Study From Pakistan. [PDF]

Cureus
Ashraf I, Khan ME, Naqvi SAR, Imran MB, Jabbar T.   +4 more
europepmc   +1 more source

Application of the AAPS (AFP-ALBI-PIVKA-II-Serum Albumin) Scoring System in Efficacy Monitoring of Hepatocellular Carcinoma Treated with PD-1 Inhibitor Combined with Transcatheter Arterial Chemoembolization (TACE). [PDF]

J Hepatocell Carcinoma
Yang H, Kong L, Ge W, Li Q.
europepmc   +1 more source

PIVKA-II come nuovo biomarcatore diagnostico nell'adenocarcinoma pancreatico: espressione sierica, tissutale e in vitro [PDF]

Il carcinoma pancreatico è la settima causa principale di decessi cancro correlati a livello globale, con un tasso medio di sopravvivenza a 5 anni di solo il 4%.
TARTAGLIONE, SARA
core